1.23 USD
▲-0.02+6.96%
盘后 1.17 +1.72%
2026-08-03
市值
$71.22M
市盈率
4.72
EPS
0.26
股息率
—
52 周区间
1.08 – 3.08
成交量
751.92K
Beta
1.49
目标价
—
52W 低 1.0852W 高 3.08
价格走势
公司简介
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, man...